Daiichi Sankyo Co., Ltd. – Sponsored ADR (OTCMKTS:DSNKY) Stock Short Interest Drops 88.8%

Daiichi Sankyo Co., Ltd. – Sponsored ADR (OTCMKTS:DSNKY) saw a large decrease in short interest in the month of October. As of October 30th, there was short interest totaling 2,140 shares, a decrease of 88.8% from the October 15th total of 19,178 shares. Currently, 0.0% of the shares of the company are sold short. Based on an average trading volume of 241,294 shares, the days-to-cover ratio is presently 0.0 days.

Wall Street Analyst Weigh In

DSNKY has been the subject of several analyst reports. Jefferies Financial Group downgraded shares of Daiichi Sankyo from a “buy” rating to a “hold” rating in a report on Thursday, July 30th. Zacks Research downgraded shares of Daiichi Sankyo from a “hold” rating to a “strong sell” rating in a research note on Tuesday, October 20th. One analyst has rated the stock with a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, Daiichi Sankyo presently has an average rating of “Reduce”.

Daiichi Sankyo Stock Performance

OTCMKTS:DSNKY opened at $17.90 on Friday. The business has a 50 day moving average of $17.78 and a 200 day moving average of $17.55. The company has a market capitalization of $33.35 billion, a price-to-earnings ratio of 18.27, a PEG ratio of 2.00 and a beta of -0.10. Daiichi Sankyo has a 1-year low of $14.98 and a 1-year high of $24.77. The company has a debt-to-equity ratio of 0.29, a current ratio of 2.92 and a quick ratio of 1.96.

Daiichi Sankyo (OTCMKTS:DSNKY) last issued its quarterly earnings results on Friday, October 30th. The company reported $0.29 EPS for the quarter, beating analysts’ consensus estimates of $0.21 by $0.08. The business had revenue of $3.77 billion for the quarter, compared to analysts’ expectations of $3.58 billion. Daiichi Sankyo had a net margin of 12.13% and a return on equity of 16.31%. On average, sell-side analysts predict that Daiichi Sankyo will post 0.87 earnings per share for the current fiscal year.

Daiichi Sankyo Company Profile

Daiichi Sankyo is a Japan-based pharmaceutical company that researches, develops, manufactures and markets medicines. Formed in 2005 through the merger of Sankyo and Daiichi Pharmaceutical, the company has a particular focus on oncology and also develops treatments in areas such as cardiovascular disease and other serious conditions. Its portfolio includes Enhertu (trastuzumab deruxtecan), an antibody-drug conjugate developed in collaboration with AstraZeneca, as well as medicines such as Lixiana (edoxaban) and Vanflyta (quizartinib).